InChI: | InChI=1/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1 |
Specification: |
The IUPAC name of Bleomycin is 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium. With the CAS registry number 11056-06-7, it is also named as Bleomycinum. The classification codes are Antibiotics, antineoplastic; Antineoplastic Agents; Drug / Therapeutic Agent; Human Data; Mutation data; Reproductive Effect; Skin / Eye Irritant; Tumor data. It is colourless or light yellow powder which is a glycopeptide antibiotic produced by the bacterium Streptomyces verticillus. And it is nonflammable. When heated to decomposition Bleomycin emits toxic fumes of NOx.
The other characteristics of this product can be summarized as: (1)#H bond acceptors: 38; (2)#H bond donors: 25; (3)#Freely Rotating Bonds: 45; (4)Polar Surface Area: 418.05 ?2; (5)Rotatable Bond Count: 36; (6)Tautomer Count: 1000; (7)Exact Mass: 1414.51898; (8)MonoIsotopic Mass: 1414.51898; (9)Topological Polar Surface Area: 685; (10)Heavy Atom Count: 96; (11)Formal Charge: 1; (12)Complexity: 2580; (13)Defined Atom StereoCenter Count: 18; (14)Undefined Atom StereoCenter Count: 1; (15)Covalently-Bonded Unit Count: 1.
Uses of Bleomycin: It is used as an anti-cancer agent, and its chemotherapeutical forms are primarily Bleomycin A2 (shown in the image) and B2. Bleomycin A2 is used as a component of the ABVD regimen in the treatment of Hodgkin lymphoma, squamous cell carcinomas, and testicular cancer, as well as in the treatment of pleurodesis and plantar warts. But this drug has many side effects. The most serious complication of bleomycin is pulmonary fibrosis and impaired lung function
When you are using this chemical, please be cautious about it as the following:
It has limited evidence of a carcinogenic effect. And it may cause heritable genetic damage. If you want to contact this product, you must wear suitable protective clothing and gloves. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
People can use the following data to convert to the molecule structure.
1. SMILES:O=C(N)[C@@H](N)CN[C@H](c1nc(N)c(c(n1)C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@@H](C(=O)N[C@H](C(=O)NCCc2nc(cs2)c3nc(C(=O)NCCC[S+](C)C)cs3)[C@H](O)C)C)C(O[C@@H]5O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]5O[C@H]4O [C@H](CO)[C@@H](O)[C@H](OC(=O)N)[C@@H]4O)c6cncn6)C)CC(=O)N
2. InChI:InChI=1/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41,42-,43-,53+,54-/m0/s1
The following are the toxicity data which has been tested.
Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
dog |
LD |
oral |
> 100mg/kg (100mg/kg) |
|
Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975. |
human |
LDLo |
intramuscular |
418mg/kg (418mg/kg) |
LUNGS, THORAX, OR RESPIRATION: FIBROSING ALVEOLITIS
LUNGS, THORAX, OR RESPIRATION: DYSPNEA |
American Journal of Clinical Pathology. Vol. 58, Pg. 501, 1972.
|
human |
LDLo |
intravenous |
351mg/kg (351mg/kg) |
LUNGS, THORAX, OR RESPIRATION: FIBROSING ALVEOLITIS
LUNGS, THORAX, OR RESPIRATION: DYSPNEA |
American Journal of Clinical Pathology. Vol. 58, Pg. 501, 1972.
|
mouse |
LD50 |
intramuscular |
270mg/kg (270mg/kg) |
|
Pharmaceutical Chemistry Journal Vol. 17, Pg. 785, 1983. |
mouse |
LD50 |
intraperitoneal |
35mg/kg (35mg/kg) |
|
Journal of Antibiotics. Vol. 37, Pg. 239, 1984. |
mouse |
LD50 |
intravenous |
53mg/kg (53mg/kg) |
|
Journal of Antibiotics. Vol. 31, Pg. 667, 1978. |
mouse |
LD50 |
oral |
> 2gm/kg (2000mg/kg) |
|
Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975. |
mouse |
LD50 |
subcutaneous |
188mg/kg (188mg/kg) |
|
Yakkyoku. Pharmacy. Vol. 25, Pg. 573, 1974. |
mouse |
LDLo |
intratracheal |
14mg/kg (14mg/kg) |
|
Toxicology Letters. Vol. 30, Pg. 63, 1986. |
rat |
LD |
oral |
> 200mg/kg (200mg/kg) |
|
Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975. |
rat |
LD50 |
intraperitoneal |
168mg/kg (168mg/kg) |
|
"Bleomycin: Current Status and New Development, Papers Presented in a Symposium, Oakland, CA, 1977," Carter, S.K., et al., eds., New York, Academic Press, Inc., 1978Vol. -, Pg. 311, 1978. |
rat |
LD50 |
subcutaneous |
168mg/kg (168mg/kg) |
|
Yakkyoku. Pharmacy. Vol. 25, Pg. 573, 1974. |
rat |
LDLo |
intratracheal |
4units/kg (4units/kg) |
LUNGS, THORAX, OR RESPIRATION: STRUCTURAL OR FUNCTIONAL CHANGE IN TRACHEA OR BRONCHI
LUNGS, THORAX, OR RESPIRATION: FIBROSIS (INTERSTITIAL)
LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA |
Lung. Vol. 161, Pg. 287, 1983.
|
|